Undisclosed TCR-T/CAR-T Pipeline

About Neomics Pharmaceuticals

Neomics Pharmaceuticals, founded in 2017 and based in Paris, is a preclinical biotech innovator in the cell and gene therapy space. The company's core technology is a proprietary third-generation CAR platform designed to overcome historical expression challenges, aiming to produce T cell therapies with superior expansion, persistence, and clinical efficacy. While still in early development, Neomics is building a pipeline of TCR-T and CAR-T candidates targeting a broad range of cancers, positioning itself in the competitive but high-potential field of next-generation immuno-oncology.

Therapeutic Areas